
Protein binding
Cyprotex is a specialist provider of ADME and PK services and provide a range of in vitro protein binding assays.
Plasma protein binding
Plasma protein binding plays an important role in the distribution and pharmacokinetics (PK) of a potential drug. In general, only unbound drug is available for passive diffusion to extravascular or tissue sites where therapeutic effects occur and therefore plasma protein binding is an important determinant of drug efficacy.
As part of our portfolio of Cloe Screen ADME/PK services, Cyprotex provide a plasma protein binding service for a wide range of species. For more background information on plasma protein binding studies, see our online ADME guide.
Brain tissue binding
If a link between exposure and CNS efficacy is required then it is important to investigate the binding capacity of the brain tissue in combination with total brain levels and BBB permeability.
Cyprotex provide a brain tissue binding service as well as MDR1-MDCK permeability and brain to plasma ratio services.
Blood to plasma ratio
Parameters determined using plasma data (e.g., pharmacokinetic parameters) may be misleading if concentrations of drug differ between plasma and red blood cells as a consequence of differential binding to a specific component in the blood. The blood to plasma ratio determines the concentration of the drug in whole blood compared to plasma and provides an indication of drug binding to erythrocytes.
Cyprotex offer a blood to plasma ratio service for a wide range of different species.
Microsomal binding
Drug that is sequestered in microsomes in vitro is presumed to be unavailable for direct interaction with metabolising enzymes, just as drug that is bound to plasma proteins and tissue macromolecules in vivo is presumed to be unable to be directly acted on by drug metabolising enzymes. Microsomal binding is an important factor in the prediction of in vivo pharmacokinetics from in vitro drug metabolism data and the prediction of drug-drug interactions.
Cyprotex offer a microsomal binding service for a range of different species.

Genomic ADME - gADME™
Cyprotex's proprietary gADME™ system can alert you to genetic variations in drug metabolism, allowing for personalised doses, drug rescue and repositioning.
Learn more about gADME
In vitro Micronucleus Test
Cyprotex now offers the in vitro micronucleus test for genotoxicity assessment using an automated, high content screening method for improved detection and reliability.
Learn more about our in vitro MNT service
Drug Transporters
Cyprotex provides a full range of drug-transporter studies as recommended by the ITC white paper and EMA guidelines.
Learn more about transporters

By Dr. Katya Tsaioun, Chief Scientific Officer, Cyprotex
Wiley & Sons, March 2011






